Abliva can look back on an eventful year, which was marked by the strategy shift towards treatments for mitochondrial diseases made last year. Several important milestones have been passed – including two successful rights issues that together raised 74 MSEK. The company has also received green lights from the FDA and MHRA regarding an accelerated development plan, and it is now working intensively to realize that plan during the year to come. BioStock has spoken to CEO Erik Kinnman to hear his thoughts on what to expect next for Abliva.
Read the full article at biostock.se:
https://www.biostock.se/en/ablivas-kl1333-heading-for-phase-ii-iii-in-2021/
This is a press release from BioStock – Connecting Innovation & Capital. https://www.biostock.se